

A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS

(Alphabetisch nach Erstautor sortiert)

1. ANDERMATT S, **PAPADOPOULOU A**, RADUE EW, SPRENGER T, CATTIN P
Tracking the evolution of cerebral Gadolinium-enhancing lesions to persistent T1 black holes in Multiple Sclerosis: Validation of a semiautomated pipeline
J Neuroimaging 2017; 27(5):469-475. IF: 1.664
2. ASGARI N, FLANAGAN EP, FUJIHARA K, KIM HJ, SKEJOE HP, **WUERFEL J**, KURODA H, KIM SH, MAILLART E, MARIGNIER R, PITTOCK SJ, PAUL F, WEINSHENKER BG
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
Neurol Neuroimmunol Neuroinflamm. 2017; 4(4):e343. IF: -
3. AUBERT-BROCHE B, **WEIER K**, LONGONI G, FONOVS, BAR-OR A, MARRIE RA, YEH EA, NARAYANAN S, ARNOLD DL, VERHEY LH, BANWELL B, COLLINS L
Monophasic demyelination reduces brain growth in children
Neurology 2017; 88(18), 1744-1750. IF: 8.320
4. BABILONI C, DEL PERCIO C, LIZIO R, NOCE G, CORDONE S, LOPEZ S, SORICELLI A, FERRI R, PASCARELLI MT, NOBILI F, ARNALDI D, AARSLAND D, ORZI F, BUTTINELLI C, GIUBILEI F, ONOFRJ M, STOCCHI F, STIRPE P, **FUHR P**, **GSCHWANDTNER U**, RANSMAYR G, CARAVIAS G, GARN H, SORPRESI F, PIEVANI M, FRISONI GB, D'ANTONIO F, DE LENA C, GÜNTEKIN B, HANOGLU L, BASAR E, YENER G, EMEK-SAVAS DD, TRIGGIANI AI, FRANCIOTTI R, DE PANDIS MF, BONANNI L
Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study
Neurobiology of aging 2017; 55: 143-158. IF: 5.117
5. BABILONI C, DEL PERCIO C, LIZIO R, NOCE G, CORDONE S, LOPEZ S, SORICELLI A, FERRI R, PASCARELLI MT, NOBILI F, ARNALDI D, FAMA F, AARSLAND D, ORZI F, BUTTINELLI C, GIUBILEI F, ONOFRJ M, STOCCHI F, STIRPE P, **FUHR P**, **GSCHWANDTNER U**, RANSMAYR G, CARAVIAS G, GARN H, SORPRESI F, PIEVANI M, D'ANTONIO F, DE LENA C, GÜNTEKIN B, HANOGLU L, BASAR E, YENER G, EMEK-SAVAS DD, TRIGGIANI AI, FRANCIOTTI R, FRISONI GB, BONANNI L, DE PANDIS MF
Abnormalities of cortical neural synchronization mechanisms in subject with mild cognitive impairment due to Alzheimer's and Parkinson's disease: an EEG study
Journal of Alzheimer's Disease 2017; 59: 339-358. IF: 3.731
6. **BARRO C**, LEOCANI L, **LEPPERT D**, COMI G, **KAPPOS L**, **KUHLE J**
Fluid biomarker and electrophysiological outcome measures for progressive MS trials.
Mult Scler J 2017; 23(12): 1600-1613 IF: 4.840
7. BAUER J, BECKER AJ, ELYAMAN W, PELTOLA J, **RÜEGG S**, TITULAER MJ, VARLEY JA, BEGHI E
Innate and adaptive immunity in human epilepsies
Epilepsia 2017; 58(Suppl. 3): S57-S68. IF: 5.295
8. **BISCHOF A**, MANIGOLD T, **BARRO C**, HEIJNEN I, BERGER CT, **DERFUSS T**, **KUHLE J**, DAIKELER T
Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy
Ann Rheum Dis. 2017 Juli 25. [Epub ahead of print] IF: 12.811
9. **BONATI U**, HOLIGA Š, HELLBACH N, RISTERUCCI C, BERGAUER T, TANG W, HAFNER P, THOENI A, BIERI O, GERLACH I, MARQUET A, KHWAJA O, SAMBATARO F, BERTOLINO A, DUKART J, FISCHMANN A, FISCHER D, CZECH C
Longitudinal characterization of biomarkers for spinal muscular atrophy
Ann Clin Transl Neurol. 2017; 4(5): 292-304. IF 3.901
10. BOVE R, CHITNIS T, CREE BA, TINTORÉ M, **NAEGELIN Y**, UITDEHAAG BM, **KAPPOS L**, KHOURY SJ, MONTALBAN X, HAUSER SL, WEINER HL; SUMMIT Consortium
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts
Mult Scler J 2017 Aug 1. [Epub ahead of print] IF: 4.840
11. BREGERE C, **FISCH U**, SAILER MH, LIEB WS, CHICHA L, GOEPFERT F, KREMER T, GUZMAN R
Neonatal hypoxia-ischemia in rat increases doublecortin concentration in the cerebrospinal fluid
Eur J Neurosci. 2017; 46(2): 1758-1767. IF: 2.941
12. BRIDEL C, KOEL-SIMMELINK MJA, PEFFEROEN L, DERADA TROLETTI C, DURIEUX S, GORTER R, NUTMA E, GAMI P, IACOBEOUS E, BRUNDIN L, **KUHLE J**, VRENKEN H, KILLESTEIN J, PIERSMA SR, PHAM TV, DE VRIES HE, AMOR S, JIMENEZ CR, TEUNISSEN CE
Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro
Neuropathol Appl Neurobiol. 2017 May 24. [Epub ahead of print] IF: 5.347

13. **BROCKHOFF M**, RION N, CHOJNOWSKA K, **WIKTOROWICZ T**, EICKHORST C, **ERNE B**, FRANK S, ANGELINI C, FURLING D, RÜEGG MA, **SINNREICH M***, **CASTETS P*** (* Co-Corresponding authors)
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I
J Clin Invest. 2017; 127(2): 549-563. IF 12.78
14. **CHATURVEDI M**, **HATZ F**, **GSCHWANDTNER U**, **BOGAARTS JG**, **MEYER A**, **FUHR P**, ROTH V
Quantitative EEG (QEEG) measures differentiate Parkinson's disease (PD) patients from healthy controls (HC)
Frontiers in Aging Neuroscience 2017; 9: 3. IF: 4.504
15. CHEN X, SIEBOURG-POLSTER J, WOLF D, CZECH C, **BONATI U**, FISCHER D, KHWAJA O, STRAHM M
Feasibility of using Microsoft Kinect to assess upper limb movement in Type III spinal muscular atrophy patients
PLoS One 2017; 12(1): e0170472. IF 2.806
16. COHAN S, **KAPPOS L**, GIOVANNONI G, WIENDL H, SELMAJ K, HAVRDOVA E, ROSE J, GREENBERG S, PHILLIPS G, MA W, WANG P, LIMA G, SABATELLA G
Efficacy of Daclizumab beta versus intramuscular Interferon Beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
Mult Scler. 2017 Oct 1. [Epub ahead of print] IF: 4.840
17. COMI G, DE STEFANO N, FREEDMAN MS, BARKHOF F, UITDEHAAG BMJ, DE VOS M, MARHARDT K, CHEN L, ISSARD D, **KAPPOS L**
Subcutaneous interferon β -1a in the treatment of clinically isolated syndromes: 3- and 5-year results of the Phase III dosing frequency-blind, multicentre REFLEXION study
J Neurol Neurosurg Psychiatry 2017; 88(4): 285-294. IF: 7.349
18. CONEN D, RODONDI N, MUELLER A, BEER J, AURICCHIO A, AMMANN P, HAYOZ D, KOBZA R, MOSCHOVITIS G, SHAH D, SCHLAEPFER J, NOVAK J, DI VALENTINO M, ERNE P, STICHERLING C, **BONATI L**, EHRET G, ROTEN L, FISCHER U, MONSCH A, STIPPICH C, **WUERFEL J**, SCHWENKGLLENKS M, KUEHNE M, OSSWALD S
Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): Structural brain damage and cognitive decline among patients with atrial fibrillation
Swiss Med Wkly. 2017; 147: w14467. IF: 1.654
19. **COZAC VV**, **BOGAARTS JG**, **CHATURVEDI M**, **GSCHWANDTNER U**, **MEYER A**, WELGE-LÜSSEN A, **FUHR P**
Among early appearing non-motor signs of Parkinson's disease, alteration of olfaction but not electroencephalographic spectrum correlates with motor function
Frontiers in Neurology 2017; 8: 545 IF: 3.552
20. DATTA E, PAPANUTTO N, **SCHLAEGER R**, ZHU A, CARBALLIDO-GAMIO J, HENRY RG
Gray matter segmentation of the spinal cord with active contours in MR images
Neuroimage 2017; 147: 788-799. IF 5.835
21. **DE MARCHIS GM**, SCHAAD C, FUNG C, BECK J, GRALLA J, TAKALA J, JAKOB SM
Gender-related differences in aneurysmal subarachnoid hemorrhage: A hospital based study
Clin Neurol Neurosurg. 2017; 157: 82-87. IF: 1.381
22. **DE MARCHIS GM**, KATAN M, **BARRO C**, **FLADT J**, **TRAENKA C**, **SEIFFGE DJ**, **HERT L**, **GENSICKE H**, **SUTTER R**, **PETERS N**, SARIKAYA H, GOEGGEL-SIMONETTI B, EL-KOUSSY M, **ENGELTER S**, **LYRER P**, CHRIST-CRAIN M, ARNOLD M, **KUHLE J**, **BONATI L**
Serum neurofilament light chain in patients with acute cerebrovascular events
Eur J Neurol 2017 Dec. 27. [Epub ahead of print] IF: 3.988
23. **DERFUSS T***, KOVARIK JM*, **KAPPOS L**, SVELIEVA M, CHHABRA R, THAKUR A, ZHANG Y, WIENDL H, TOMIC D (*co-lead authors)
 α 4-integrin receptor desaturation and disease activity return after natalizumab cessation
Neurol Neuroimmunol Neuroinflamm. 2017; 4(5):e388. IF: -
24. DE SITTER A, STEENWIJK M, RUET A, VERSTEEG A, LI Y, VAN SCHIJNDEL R, POUWELS P, KILSDONK I, COVER K, VAN DIJK B, ROPELE S, ROCCA M, YIANNAKAS M, WATTJES M, DAMANGIR S, FRISONI G, ROVIRA A, SASTRE-GARRIGA J, ENZINGER C, FILIPPI M, FREDERIKSEN J, CICCARELLI O, **KAPPOS L**, BARKHOF F, VRENKEN H
Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study
Neuroimage 2017; 163:106-114. IF: 5.835
25. DE WAARD DD, HALLIDAY A, DE BORST GJ, BULBULIA R, HUIBERS A, CASANA R, **BONATI L**, TOLVA V and GROUP A-C
Choices of stent and cerebral protection in the ongoing ACST-2 Trial: A descriptive study
Eur J Vasc Endovasc Surg. 2017;53:617-25. IF: 4.061
26. **DISANTO G**, **BARRO C**, BENKERT P, **NAEGELIN Y**, SCHÄDELIN S, GIARDIELLO A, ZECCA C, BLENNOW K, ZETTERBERG H, **LEPPERT D**, **KAPPOS L**, **GOBBI C**, **KUHLE J**; Swiss Multiple Sclerosis Cohort Study Group (including **DERFUSS T**)
Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis
Ann Neurol. 2017; 81(6): 857-870. IF: 9.890
27. **D'SOUZA M**, **YALDIZLI Ö**, JOHN R, VOGT DR, **PAPADOPOULOU A**, LUCASSEN E, MENEGOLA M, ANDELOVA M, DAHLKE F, SCHNYDER F, **KAPPOS L**
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Mult Scler J 2017; 23(4):597-603 IF: 4.840

28. DUSEK P, BAHN E, LITWIN T, JABŁONKA-SALACH K, ŁUCIUK A, HUELNHAGEN T, MADAI VI, DIERINGER MA, BULSKA E, KNAUTH M, NIENDORF T, SOBESKY J, PAUL F, SCHNEIDER SA, CZLONKOWSKA A, BRÜCK W, WEGNER C, **WUERFEL J**
Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study
Neuropathol Appl Neurobiol. 2017; 43(6): 514-532. IF: 5.347
29. EICHELBERGER D, CALABRESE P, **MEYER A, CHATURVEDI M, HATZ F, FUHR P, GSCHWANDTNER U**
Correlation of visuospatial ability and EEG slowing in patients with Parkinson's disease
Parkinson's Dis. 2017; 2017: 3659784. IF: 1.702
30. FERNÁNDEZ O, DELVECCHIO M, EDAN G, FREDRIKSON S, GIONVANNONI G, HARTUNG HP, HAVRDOVA E, **KAPPOS L**, POZZILLI C, SOERENSEN PS, TACKENBERG B, VERMERSCH P, COMI G
Survey of diagnostic and treatment practices for multiple sclerosis in Europe
Eur J Neurol. 2017; 24(3):516-522 IF: 3.988
31. FITZGERALD KC, MUNGER KL, FREEDMAN MS, HARTUNG HP, MILLER DH, MONTALBAN X, EDAN G, BARKHOF F, WICKLEIN M, **RADUE EW, KAPPOS L**, POHL C†, ASCHERIO A
Sodium intake and multiple sclerosis activity and progression in BENEFIT
Ann Neurol. 2017; 82(1):20-29 IF: 9.890
32. FREEDMAN MS, WOLINSKY JS, COMI G, **KAPPOS L**, OLSSON TP, MILLER AE, THANGAVELU K, BENAMOR M, TRUFFINET P, O'CONNOR PW for the TEMSO and TOWER Study Groups
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
Mult Scler J 2017 Mar. [Epub ahead of print] IF: 4.840
33. FREY N, BODMER M, BIRCHER A, **RÜEGG S**, JICK SS, MEIER CR, SPÖNDLIN J.
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. A UK-based case-control study
Epilepsia 2017; 58(12): 2178-2185. IF: 5.295
34. GATTRINGER T, PINTER D, ENZINGER C, SEIFERT-HELD T, KNEIHSL M, FANDLER S, PICHLER A, **BARRO C, GRÖBKE S**, VOORTMAN M, PIRPAMER L, HOFER E, ROPELE S, SCHMIDT R, **KUHLE J**, FAZEKAS F, KHALIL M
Serum neurofilament light is sensitive to active cerebral small vessel disease
Neurology 2017; 89(20): 2108-2114. IF: 8.320
35. **GENSICKE H**, FRIH A, STRBIAN D, ZINI A, PEZZINI A, PADJEN V, HAUETER M, **SEIFFGE DJ**, MAKITIE L, **TRAENKA C**, POLI L, MARTINEZ-MAJANDER N, PUTAALA J, **BONATI L**, SIBOLT G, GIOVANNINI G, CURTZE S, BESLAC-BUMBASIREVIC L, VANDELLI L, **LYRER PA**, NEDERKOORN PJ, TATLISUMAK T, **ENGELTER ST**
Prognostic significance of proteinuria in stroke patients treated with intravenous thrombolysis
Eur J Neurol 2017; 2: 262-269. IF: 3.988
36. GIESS RM, PFUHL C, BEHRENS JR, RASCHE L, FREITAG E, KHALIGHY N, OTTO C, **WUERFEL J**, BRANDT AU, HOFMANN J, EBERSPÄCHER B, BELLMANN-STROBL J, PAUL F, RUPRECHT K
Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis
PLoS One 2017; 12(4):e0175279. IF: 2.806
37. GOLD R, ARNOLD DL, BAR-OR A, HUTCHINSON M, **KAPPOS L**, HAVRDOVA E, MACMANUS D, YOUSRY TA, POZZILLI C, SELMAJ K, SWEETSER MT, ZHANG R, YANG M, POTTS J, NOVAS M, MILLER DH, KURUKULASURIYA NC, FOX RJ, PHILLIPS JT
Long-term effects of delayed-release Dimethyl Fumarate in Multiple Sclerosis: Interim analysis of ENDORSE, a randomized extension study
Mult Scler J 2017; 23(2):253-265. IF: 4.840
38. GROND-GINSBACH C, CHEN B, KRAWCZAK M, PJONTEK R, GINSBACH P, JIANG Y, ABOUD S, ARNOLD ML, BERSANO A, BRANDT T, CASO V, DEBETTE S, DICHGANS M, GESCHWENDTNER A, GIACALONE G, MARTIN JJ, METSO AJ, METSO TM, GRAU AJ, KLOSS M, LICHY C, PEZZINI A, **TRAENKA C**, SCHREIBER S, THIJS V, TOUZE E, DEL ZOTTO E, TATLISUMAK T, LEYS D, **LYRER PA, ENGELTER ST** and GROUP C
Genetic Imbalance in Patients with Cervical Artery Dissection
Curr Genomics 2017; 18: 206-13. IF: 1.835
39. GROND-GINSBACH C, BRANDT T, KLOSS M, AKSAY S, **LYRER PA, TRAENKA C**, ERHART P, MARTIN J, ALTINTAS A, DE FREITAS G, THIE A, MACHETANZ J, DICHIGANS M, STROM T, **ENGELTER ST**
Next generation sequencing analysis of patients with familial cervical artery dissection
European Stroke Journal 2017 Feb. 9. [Epub ahead of print] IF: -
40. **HADINIA A, MEYER A**, BRUEGGER V, **HATZ F, NOWAK K**, TAUB E, NYBERG E, STIEGLITZ RD, **FUHR P GSCHWANDTNER U**
Cognitive behavioral group therapy reduces stress and improves the quality of life in patients with Parkinson's disease
Frontiers in Psychology 2017; 7:1975. IF: 2.323

41. HANSEN H, MINGHETTI A, **MAGON S**, ROSSMEISLA, **PAPADOPOULOU A**, KLENK C, SCHMIDT-TRUCKSÄSS A, FAUDE O, ZAHNER L, **SPRENGER T**, DONATH L
Superior effects of high-intensity interval training vs. moderate continuous training on arterial stiffness in episodic migraine: A randomized controlled trial
Front Physiol. 2017; 8: 1086. IF: 4.134
42. HANSEN H, MINGHETTI A, **MAGON S**, ROSSMEISLA, **RASENACK M**, **PAPADOPOULOU A**, KLENK C, FAUDE O, ZAHNER L, **SPRENGER T**, DONATH L
Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial
Scand J Med Sci Sports. 2017 Nov 21. [Epub ahead of print] IF: 3.331
43. **HATZ F**, **MEYER A**, **ZIMMERMANN R**, **GSCHWANDTNER U**, **FUHR P**
Apathy in patients with Parkinson's disease correlates with alteration of left fronto-polar electroencephalographic connectivity
Frontiers in Aging Neuroscience 2017; 9: 262. IF: 4.504
44. HAUSER SL*, BAR-OR A, COMI GC, GIOVANNONI G, HARTUNG HP, HEMMER B, LUBLIN F, MONTALBAN X, RAMMOHAN K, SELMAJ K, TRABOULSEE A, WOLINSKY JS, ARNOLD DL, KLINGELSCHEMITT G, MASTERMAN D, FONTOURA P, BELACHEW S, CHIN P, MAIRON N, GARREN H, **KAPPOS L*** on behalf of the OPERA I and II clinical investigators (* Co-primary authors)
Ocrelizumab versus Interferon β -1a in Relapsing Multiple Sclerosis: Two Studies
N Engl J Med 2017; 376(3):221-234. IF: 72.406
45. HAVRDOVA E, GIOVANNONI G, GOLD R, FOX RJ, **KAPPOS L**, PHILLIPS JT, OKWUOKENYE M, MARANTZ JL*
Effect of Delayed-Release Dimethyl Fumarate on No Evidence of Disease Activity in Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of the Phase III DEFINE and CONFIRM Studies
Eur J Neurol. 2017; 24(5): 726-733. IF: 3.988
46. **HERRENDORFF R**, HÄNGGI P, PFISTER H, YANG F, DEMEESTERE D, HUNZIKER F, FREY S, SCHAEREN-WIEMERS N, **STECK AJ**, ERNST B
Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy
Proc Natl Acad Sci U S A. 2017; 114(18): E3689-E3698. IF: 9.661
47. HOLLINGER A, LEDERGERBER K, VON FELTEN S, SUTTER R, **RÜEGG S**, GANTNER L, ZIMMERMANN S, BLUM A, STEINER LA, SIEGEMUND M
Comparison of propofol and dexmedetomidine infused over night to treat hyperactive and mixed ICU delirium – a protocol for the Basel ProDex clinical trial
BMJ Open 2017; 7(7):e015783. IF 2.369
48. **KAPPOS L**, ARNOLD DL, BAR-OR A, CAMM AJ, **DERFUSS T**, **SPRENGER T**, DAVIES M, PIOTROWSKA A, NI P, HARADA T
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
Mult Scler. 2017 Sept 1. [Epub ahead of print] IF: 4.840
49. **KAPPOS L**, HAVRDOVA E, GIOVANNONI G, KHATRI B, GAUTHIER S, GREENBERG S, YOU P, WANG P, GIANNATTASIO G
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing remitting multiple sclerosis in the DECIDE study
Mult Scler J 2017; 23(13): 1736-1747 IF: 4.840
50. **KAPPOS L**, TROJANO M, BUTZKUEVEN H, WIENDL H, SPELMAN T, PELLEGRINI F, CHEN Y, DONG Q, KOENDGEN H, BELACHEW S; on behalf of the Tysabri® Observational Program (TOP) Investigators
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
Mult Scler J 2017 May 1. [Epub ahead of print] IF: 4.840
51. KISTNER A, BIGLER MB, GLATZ K, EGLI SB, BALDIN FS, MARQUARDSEN FA, **MEHLING M**, RENTSCH KM, STAUB D, ASCHWANDEN M, RECHER M, DAIKELER T, BERGER CT
Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis
Rheumatology (Oxford). 2017; 56(5): 829-834. IF 4.818
52. **KUHLE J**, NOURBAKSH B, GRANT D, MORANT S, **BARRO C**, **YALDIZLI Ö**, PELLETIER D, GIOVANNONI G, WAUBANT E, GNANAPAVAN S
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Neurology 2017; 88(9): 826-831. IF: 8.320
53. LAW ZK, MERETOJAA, **ENGELTER ST**, CHRISTENSEN H, MURESAN EM, GLAD, SB, LIU L, BATH PM, SPRIGG N,
Treatment of intracerebral haemorrhage with tranexamic acid - A review of current evidence and ongoing trials
European Stroke Journal 2017; 2(1):13-22. IF: -

54. LIEM MI, KENNEDY F, **BONATI LH**, VAN DER LUGT A, COOLEN BF, NEDERVEEN AJ, JAGER HR, BROWN MM and NEDERKOORN PJ
Investigations of Carotid Stenosis to Identify Vulnerable Atherosclerotic Plaque and Determine Individual Stroke Risk
Circ J. 2017; 81:1246-53. IF: 19.309
55. LINK J, RAMANUJAM R, AUER M, **RYNER M**, HÄSSLER S, BACHELET D, MBOGNING C, WARNKE C, BUCK D, HYLDGAARD JENSEN PE, **SIEVERS C**, INGENHOVEN K, FISSOLO N, **LINDBERG RLP**, GRUMMEL V, DONNELLAN N, COMABELLA M, MONTALBAN X, KIESEIER B, SOELBERG SØRENSEN P, HARTUNG HP, **DERFUSS T**, LAWTON A, SIKKEMA D, PALLARDY M, HEMMER B, DEISENHAMMER F, BROËT P, DÖNNES P, DAVIDSON J, FOGDELL-HAHN A; ABIRISK Consortium
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
PLoS One 2017; 12(2):e0170395. IF: 2.806
56. **LORSCHIEDER J**, JOKUBAITIS VG, SPELMAN T, IZQUIERDO G, LUGARESI A, HAVRDOVA E, HORAKOVA D, TROJANO M, DUQUETTE P, GIRARD M, PRAT A, GRANDMAISON F, GRAMMOND P, PUCCI E, BOZ C, SOLA P, FERRARO D, SPITALERI D, LECHNER-SCOTT J, TERZI M, VAN PESCH V, IULIANO G, BERGAMASCHI R, RAMOTELLO C, GRANELLA F, OREJA-GUEVARA C, BUTZKUEVEN H, KALINCIK T; MSBase Study Group
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Neurology 2017; 89(10):1050-1059. IF: 8.320
57. MONTALBAN X, HAUSER SL, **KAPPOS L**, ARNOLD DL, BAR-OR A, COMI G, DE SEZE J, GIOVANNONI G, HARTUNG HP, HEMMER B, LUBLIN F, RAMMOHAN KW, SELMAJ K, TRABOULSEE A, SAUTER A, MASTERMAN D, FONTOURA P, BELACHEW S, GARREN H, MAIRON N, CHIN P, WOLINSKY JS; ORATORIO Clinical Investigators
Ocrelizumab versus placebo in Primary Progressive Multiple Sclerosis
N Engl J Med. 2017; 376(3): 209-220. IF: 72.406
58. **MULLER MD**, AHLHELM FJ, VON HESSLING A, DOIG D, NEDERKOORN PJ, MACDONALD S, **LYRER PA**, VAN DER LUGT A, HENDRIKSE J, STIPPICH C, VAN DER WORP HB, RICHARDS T, BROWN MM, **ENGELTER ST**, **BONATI LH**
Vascular anatomy predicts the risk of cerebral ischemia in patients randomized to carotid stenting versus endarterectomy
Stroke 2017; 48: 1285-92. IF: 6.032
59. NAVARINI AA, HRUZ P, BERGER CT, HOU TZ, SCHWAB C, GABRYSCH A, HIGGINS R, FREDE N, PADBERG SGIER BC, KÄMPE O, BURGÈNER AV, MARQUARDSEN F, BALDIN F, BIGLER M, KISTNER A, JAUCH A, BIGNUCOLO O, MEYER B, MEIENBERG F, **MEHLING M**, JEKER LT, HEIJNEN I, DAIKELER TD, GEBBERS JO, GRIMBACHER B, SANSOM DM, JEKER R, HESS C, RECHER M
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
J Allergy Clin Immunol. 2017; 139(3): 1043-1046. IF 13.081
60. NEHA S. DANGAYACH, MD, HARPREET SINGH GREWAL, MD, **DE MARCHIS GM**, MD, MS, ROBERTA SEFCIK, BA, RACHEL BRUCE, BA, AARTI CHHATLANI, MD, E. SANDER CONNOLLY, MD, CHRISTINA FALO, PHD, SACHIN AGARWAL, MD, JAN CLAASSEN, MD, PHD, J. MICHAEL SCHMIDT, PHD, AND STEPHAN A. MAYER, MD
Does the obesity paradox predict functional outcome in intracerebral hemorrhage?
J Neurosurg. 2017 Dec 8: 1-5. [Epub ahead of print] IF: 4.059
61. NORDIN A, AKIMOTO C, WUOLIKAINEN A, ALSTERMARK H, FORSBERG K, BAUMANN P, PINTO S, DE CARVALHO M, HÜBERS A, NORDIN F, LUDOLPH AC, WEISHAUPT JH, MEYER T, GREHL T, **SCHWEIKERT K**, WEBER M, BURKHARDT C, NEUWIRTH C, HOLMØY T, MORITA M, TYSNES OB, BENATAR M, WUU J, LANGE DJ, BISGÅRD C, ASGARI N, TARVAINEN I, BRÄNNSTRÖM T, ANDERSEN PM
Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study
Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(3-4): 256-264. IF: 3.054
62. PLAVINA T, KANDADI MURALIDHARAN K, KUESTERS G, MIKOL D, EVANS K, SUBRAMANYAM M, NESTOROV I, CHEN Y, DONG Q, HO P, AMARANTE D, ADAMS A, DE SÈZE J, FOX R, GOLD R, JEFFERY D, **KAPPOS L**, MONTALBAN X, WEINSTOCK-GUTTMAN B, HARTUNG HP, CREE BA
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Neurology 2017; 89(15):1584-1593 IF: 8.320
63. **POLYMERIS AA**, STEHLE GT, MEDINGER M, **DE MARCHIS GM**
Transient focal neurologic deficits upon hematopoietic stem cell transplantation: just a coincidence?
Acta Neurol Belg. 2017 Oct. 17. [Epub ahead of print] IF: 1.722
64. PRADOS F, ASHBURNER J, BLAIOTTA C, BROSCHE T, CARBALLIDO-GAMIO J, CARDOSO MJ, CONRAD BN, DATTA E, DÁVID G, LEENER B, DUPONT SM, FREUND P, WHEELER-KINGSHOTT CAMG, GRUSSU F, HENRY R, LANDMAN BA, LJUNGBERG E, LYTTLE B, OURSELIN S, PAPANUTTO N, SAPORITO S, **SCHLAEGER R**, SMITH SA, SUMMERS P, TAM R, YIANNAKAS MC, ZHU A, COHEN-ADAD J
Spinal cord grey matter segmentation challenge
Neuroimage 2017; 152: 312-329. IF 5.835
65. **RADUE EW**, SPRENGER T, GAETANO L, **MUELLER-LENKE N**, CAVALIER S, THANGAVELU K, PANZARA MA, DONALDSON JE, WOODWARD FM, **WUERFEL J**, WOLINSKY JS, **KAPPOS L**
Teriflunomide slows BVL in relapsing MS: A re-analysis of the TEMSO MRI dataset using SIENA
Neurol Neuroimmunol Neuroinflamm. 2017; 4(5):e390 IF: -

66. RANTNER B, KOLLERITS B, ROUBIN GS, RINGLEB PA, JANSEN O, HOWARD G, HENDRIKSE J, HALLIDAY A, GREGSON J, ECKSTEIN HH, CALVET D, BULBULIA R, **BONATI LH**, BECQUEMIN JP, ALGRA A, BROWN MM, MAS JL, BROTT TG, FRAEDRICH G and the Carotid Stenosis Trialists' Collaboration
Early endarterectomy carries a lower procedural risk than early stenting in patients with symptomatic stenosis of the internal carotid artery: Results from 4 randomized controlled trials
Stroke 2017; 48:1580-87. IF: 6.032
67. RATTAY TW, WINTER N, **DÉCARD BF**, DAMMEIER NM, HAERTIG F, CEANGA M, AXER H, GRIMM A
Nerve ultrasound as follow-up tool in treated multifocal motor neuropathy
Eur J Neurol. 2017; 24(9): 1125-1134. IF: 3.988
68. RITZ MF, GROND-GINSBACH C, FLURI F, KLOSS M, TOLNAY M, **PETERS N, ENGELTER ST, LYRER PA**
Cerebral small vessel disease is associated with dysregulation in the ubiquitin proteasome system and other major cellular pathways in specific brain regions
Neurodegener Dis. 2017; 17: 261-75. IF: 2.842
69. ROLF L, MURIS AH, MATHIAS A, DU PASQUIER R, KONECZNY I, **DISANTO G, KUHLE J, RAMAGOPALAN S**, DAMOISEAUX J, SMOLDERS J, HUPPERTS R
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis
Mult Scler 2017 Jul 1. [Epub ahead of print] IF: 4.840
70. ROSE J, GIOVANNONI G, WIENDL H, GOLD R, HAVRDOVÁ E, **KAPPOS L**, SELMAJ KW, ZHAO J, RIESTER K, TSAO LC, GREENBERG SJ
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis
Mult Scler Relat Disord. 2017; 17:32-40 IF: 2.349
71. **RUST H, PETERS N**, ALLUM JHJ, WAGNER B, HONEGGER F, BAUMANN T
VEMPs in a patient with cerebellar ataxia, neuropathy and vestibular areflexia (CANVAS)
J Neurol Sci. 2017; 378:9-11. IF: 2.295
72. SADEGHI BAHMANI D, CALABRESE P, MERKT H, **NAEGELIN Y**, GERBER M, PÜHSE U, HOLSBOER-TRACHSLER E, BRAND S
Multiple Sclerosis: Associations between physical disability and depression are not mediated by self-reported physical activity
Percept Mot Skills 2017; 124(5): 974-991. IF: 0.626
73. **SANDERSON NS, ZIMMERMANN M**, EILINGER L, GUBSER C, SCHAEREN-WIEMERS N, **LINDBERG RLP**, DOUGAN SK, PLOEGH HL, **KAPPOS L, DERFUSS T**
Cocapture of cognate and bystander antigens can activate autoreactive B cells
Proc Natl Acad Sci USA. 2017;114(4):734-739. IF: 9.661
74. SCHEITZ JF, TURC G, KUJALA L, **POLYMERIS AA**, HELDNER MR, ZONNEVELD TP, ERDUR H, CURTZE S, **TRAENKA C**, BRENIERE C, WIEST R, ROCCO A, SIBOLT G, **GENSICKE H**, ENDRES M, MARTINEZ-MAJANDER N, BEJOT Y, NEDERKOORN PJ, OPPENHEIM C, ARNOLD M, **ENGELTER ST**, STRBIAN D, NOLTE CH
Intracerebral hemorrhage and outcome after thrombolysis in stroke patients using selective serotonin-reuptake inhibitors
Stroke 2017; 48(12): 3239-3244. IF: 6.032
75. SCHLEMM L, CHIEN C, BELLMANN-STROBL J, DÖRR J, **WUERFEL J**, BRANDT AU, PAUL F, SCHEEL M
Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients
Mult Scler. 2017; 23(7): 963-972. IF: 4.840
76. **SEIFFGE DJ, DE MARCHIS GM**
Author response: Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events
Neurology 2017; 21: 2068. IF: 8.320
77. **SEIFFGE DJ, TRAENKA C, POLYMERIS A, HERT L, FISCH U, PETERS N, DE MARCHIS GM**, GUZMAN R, NICKEL CH, **LYRER PA, BONATI LH**, TSAKIRIS D, **ENGELTER ST**
Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke
J Thromb Thrombolysis 2017; 1:112-116. IF: 2.142
78. **SEIFFGE DJ, TRAENKA C, POLYMERIS AA, THILEMANN S, WAGNER B, HERT L, MULLER MD, GENSICKE H, PETERS N, NICKEL CH, STIPPICH C, SUTTER R, MARSCH S, FISCH U, GUZMAN R, DE MARCHIS GM, LYRER PA, BONATI LH, TSAKIRIS DA, ENGELTER ST**
Intravenous thrombolysis in patients with stroke taking Rivaroxaban using drug specific plasma levels: Experience with a standard operation procedure in clinical practice
J Stroke 2017; 3:347-355. IF: 5.576
79. SEMMLACK S, YEGINSOY D, SPIEGEL R, TISLJAR K, **RÜEGG S**, MARSCH S, SUTTER R
Emergency response to out-of-hospital status epilepticus. A 10-year observational cohort study
Neurology 2017; 89(4): 376-384. IF: 8.320
80. SILGINER M, **NAGY S**, HAPPOLD C, SCHNEIDER H, WELLER M, ROTH P
Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma
Neuro Oncol. 2017; 19(10):1338-1349. IF: 7.786

81. SIMPSON KN, SIMPSON AN, MAULDIN PD, PALESCH YY, YEATTS SD, KLEINDORFER D, TOMSICK TA, FOSTER LD, DEMCHUK AM, KHATRI P, HILL MD, JAUCH EC, JOVIN TG, YAN B, VON KUMMER R, MOLINA CA, GOYAL M, SCHONEWILLE WJ, MAZIGHI M, **ENGELTER ST**, ANDERSON C, SPILKER J, CARROZZELLA J, RYCKBORST KJ, JANIS LS, BRODERICK JP and INTERVENTIONAL MANAGEMENT OF STROKE IIII
Observed cost and variations in short term cost-effectiveness of therapy for ischemic stroke in interventional management of stroke (IMS) IIII
J Am Heart Assoc. 2017; 6(5). IF: 4.863
82. SOELBERG SØRENSEN P, COMI G, VOLLMER TL, MONTALBAN X, **KAPPOS L**, DADON Y, GORFINE T, MARGALIT M, SASSON N, RUBINCHICK S, KNAPPERTZ, V
Laquinimod safety profile: Pooled Analyses from the ALLEGRO and BRAVO Trials
International Journal of MS Care 2017; 19(1): 16-24 IF: -
83. SPAANDER FH, ZINKSTOK SM, BAHAROGLU IM, **GENSICKE H**, **POLYMERIS A**, **TRAENKA C**, HAMETNER C, RINGLEB P, CURTZE S, MARTINEZ-MAJANDER N, AARNIO K, NOLTE CH, SCHEITZ JF, LEYS D, HOCHART A, PADJEN V, KAGI G, PEZZINI A, MICHEL P, BILL O, ZINI A, **ENGELTER ST**, NEDERKOORN PJ and Thrombolysis In Ischemic Stroke Patients Collaborators (TrISP)
Sex differences and functional outcome after intravenous thrombolysis
Stroke. 2017;48(3):699-703. IF: 6.032
84. SORMANI MP, **KAPPOS L**, **RADUE EW**, COHEN JA, BARKHOF F, **SPRENGER T**, PIANI MEIER D, HAERING D, TOMIC D, DE STEFANO N
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS
Mult Scler J 2017; 23(5):656-664. IF: 4.840
85. STREITBERGER KJ, FEHLNER A, PACHE F, LACHETA A, PAPAZOGLU S, BELLMANN-STROBL J, RUPRECHT K, BRANDT A, BRAUN J, SACK I, PAUL F, **WUERFEL J**
Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder
Eur Radiol. 2017; 27(5):2206-2215. IF: 3.967
86. SUTTER R, **DE MARCHIS GM**, SEMMLACK S, **FUHR P**, **RÜEGG S**, MARSCH S, ZIAI WC, KAPLAN PW
Anesthetic drugs and outcome in status epilepticus: a matched two-center study
CNS Drugs 2017; 31: 65-74. IF 4.394
87. SUTTER R, SEMMLACK S, SPIEGEL R, TISLJAR K, **RÜEGG S**, MARSCH S
Distinguishing in- and out-of-hospital status epilepticus: clinical implications from a ten-year cohort study
Eur J Neurol 2017; 24(9): 1156-1165. IF 3.988
88. TRABOULSEE A, LI D, ZHAO Y, TAM R, ZHAO G, CHENG Y, RIDDEHOUGH A, FANG J, DANGOND F, **KAPPOS L**, on behalf of the PRISMS and SPECTRIMS working groups
Subcutaneous interferon β -1a three times weekly decreases the natural evolution of gadolinium-enhancing lesions into chronic black holes in multiple sclerosis: analysis of PRISMS and SPECTRIMS trials
Mult Scler J Exp Transl Clin. 2017; 3(4):2055217317745340 IF: -
89. **TRAENKA C**, **DE MARCHIS GM**, **HERT L**, **SEIFFGE DJ**, **POLYMERIS A**, **PETERS N**, **BONATI LH**, **ENGELTER S**, **LYRER P**, **RUEGG S**, SUTTER R
Acute ischemic stroke in nonconvulsive status epilepticus-underestimated? Results from an eight-year cohort study
J Stroke 2017; 2:236-238. IF: 5.576
90. **TRAENKA C**, DOUGOUD D, SIMONETTI BG, METSO TM, DEBETTE S, PEZZINI A, KLOSS M, GROND-GINSBACH C, MAJERSIK JJ, WORRALL BB, LEYS D, BAUMGARTNER R, CASO V, BEJOT Y, COMPTER A, REINER P, THIJS V, SOUTHERLAND AM, BERSANO A, BRANDT T, **GENSICKE H**, TOUZE E, MARTIN JJ, CHABRIAT H, TATLISUMAK T, **LYRER PA**, ARNOLD M, **ENGELTER ST** and GROUP CA-PS
Cervical artery dissection in patients \geq 60 years: Often painless, few mechanical triggers
Neurology 2017; 88:1313-20. IF: 8.320
91. VAAHTOMERI K, BROWN M, HAUSCHILD R, DE VRIES I, LEITHNER AF, **MEHLING M**, KAUFMANN WA, SIXT M
Locally triggered release of the chemokine CCL21 promotes dendritic cell transmigration across lymphatic endothelia
Cell Rep. 2017; 19(5): 902-909. IF 8.282
92. VALCI L, DALOLIO M, KUHLER D, PRAVATÀ E, **GOBBI C**, REINERT M
Intradiploic encephalocele of the primary motor cortex in an adult patient: electrophysiological implications during surgery
J Neurosurg. 2017: 1-4. IF: 3.443
93. *VAN EIJK JJJ, *DALTON HR, *RIPELLINO P, MADDEN RG, JONES C, FRITZ M, **GOBBI C**, MELLI G, PASI E, HERROD J, LISSMANN RF, ASHRAF HH, ABDELRAHIM M, MASRI OAB AL, FRAGA M, BENNINGER D, KUNTZER T, AUBERT V, SAHLI R, MORADPOUR D, BLASCO-PERRIN H, ATTARIAN S, GÉROLAMI R, COLSON P, GIORDANI MT, HARTL J, PISCHKE S, LIN NX, MCLEAN BN, BENDALL RP,, PANNING M, PERON J-M, KAMAR N, IZOPET J, JACOBS BC, VAN ALFEN N, VAN ENGELEN BGM
Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy
Neurology 2017; 89(9):909-917. IF: 8.320
94. PRAVATÀ E, ROCCA MA, VALSASINA P, RICCITELLI GC, **GOBBI C**, COMI G, FALINI A, FILIPPI M
Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis
Mult Scler. 2017; 23(14):1864-1874. IF: 4.671

95. VARHAUG KN, **BARRO C**, BJØRNEVIK K, MYHR KM, TORKILDSEN Ø, WERGELAND S, BINDOFF LA, **KUHLE J**, VEDELER C
Neurofilament light chain predicts disease activity in relapsing-remitting MS
Neurol Neuroimmunol Neuroinflamm. 2017; 5(1):e422. IF: -
96. VERMERSCH P, **RADUE EW**, PUTZKI N, RITTER S, MERSCHHEMKE M, FREEDMAN MS
A comparison of multiple sclerosis disease activity after discontinuation of Fingolimod and placebo
Mult Scler J Exp Transl Clin. 2017; 3(3):2055217317730096. IF: -
97. VOIGT D, SCHEIDT U, **DERFUSS T**, BRÜCK W, JUNKER A
Expression of the antioxidative enzyme peroxiredoxin 2 in Multiple Sclerosis lesions in relation to inflammation
Int J Mol Sci. 2017; 18(4). IF: 3.226
98. VOLKERS EJ, GREVING JP, HENDRIKSE J, ALGRA A, KAPPELLE LJ, BECQUEMIN JP, **BONATI LH**, BROTT TG, BULBULIA R, CALVET D, ECKSTEIN HH, FRAEDRICH G, GREGSON J, HALLIDAY A, HOWARD G, JANSEN O, ROUBIN GS, BROWN MM, MAS JL, RINGLEB PA and Carotid Stenosis Trialists' Collaboration
Body mass index and outcome after revascularization for symptomatic carotid artery stenosis
Neurology 2017; 88: 2052-60. IF: 8.320
99. WIESLI D, **MEYER A**, **FUHR P**, **GSCHWANDTNER U**
Influence of mild cognitive impairment, depression and anxiety on the quality of life of patients with Parkinson disease
Dementia and Geriatric Cognitive Disorders 2017; 7: 297-308. IF: 3.551
100. WILSON D, **SEIFFGE DJ**, **TRAENKA C**, BASIR G, PURRUCKER JC, RIZOS T, SOBOWALE OA, SALLINEN H, YEH SJ, WU TY, FERRIGNO M, HOUBEN R, SCHREUDER F, PERRY LA, TANAKA J, BOULANGER M, AL-SHAHI SALMAN R, JAGER HR, AMBLER G, SHAKESHAFT C, YAKUSHIJI Y, CHOI PMC, STAALS J, CORDONNIER C, JENG JS, VELTKAMP R, DOWLATSHAHI D, **ENGELTER ST**, PARRY-JONES AR, MERETOJA A, WERRING DJ
Outcome of intracerebral hemorrhage associated with different oral anticoagulants
Neurology 2017; 18:1693-1700. IF: 8.320
101. WINTER N, RATTAY TW, AXER H, SCHAEFFER E, **DÉCARD BF**, GUGEL I, SCHUHMANN M, GRIMM A
Ultrasound assessment of peripheral nerve pathology in neurofibromatosis type 1 and 2
Clin Neurophysiol. 2017; 128(5): 702-706. IF: 3.866
102. ZECCA C, ANTOZZI CG, TORRI CLERICI V, FERRAZZINI M, RE, ROSSI S, **GOBBI C**
Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation
Acta Neurologica Scandinavica 2017 Dec 3. [Epub ahead of print] IF: 3.087
103. ZECCA C, DISANTO G, MÜHL S, **GOBBI C**
Subjective patient-reported versus objective adherence to subcutaneous interferon β -1a in multiple sclerosis using RebiSmart®: the CORE study
BMC Neurol. 2017; 17(1):171. IF: 2.006
104. **ZIMMER A**, COSLOVSKY M, ABRAHAM I, **DÉCARD BF**
Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study
Patient Preference and Adherence 2017; 11: 1815–1830. IF: 1.798
105. ZONNEVELD TP, CURTZE S, ZINKSTOK SM, **GENSICKE H**, MOULIN S, SCHEITZ JF, **SEIFFGE DJ**, HAMETNER C, HELDNER MR, **TRAENKA C**, ERDUR H, BAHAROGLU I, MARTINEZ-MAJANDER N, PEZZINI A, ZINI A, PADJEN V, CORREIA PN, STRBIAN D, MICHEL P, BEJOT Y, ARNOLD M, LEYS D, RINGLEB PA, TATLISUMAK T, NOLTE CH, **ENGELTER ST**, NEDERKOORN PJ
Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome
J Neurol Neurosurg Psychiatry 2017 Oct 25. [Epub ahead of print] IF: 7.349

B - BUCHBEITRÄGE, ÜBERSICHTSARBEITEN, EDITORIALS & REVIEWS

(Alphabetisch nach Erstautor sortiert)

1. **AMATO MP, DERFUSS T, HEMMER B, LIBLAU R, MONTALBAN X, SOELBERG SØRENSEN P, MILLER DH**; 2016
ECTRIMS Focused Workshop Group
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop
Mult Scler. 2017 Jan 6. [Epub ahead of print] IF: 4.840
2. **BARRO C, LEOCANI L, LEPPERT D, COMI G, KAPPOS L, KUHLE J**
Fluid biomarker and electrophysiological outcome measures for progressive MS Trials
Mult Scler, 2017; 23(12):1600-1613. IF: 4.840
3. **CZARZASTA J, HABICH A, SIWEK T, CZAPLIŃSKI A, MAKSYMOWICZ W, WOJTKIEWICZ J**
Stem cells for ALS: An overview of possible therapeutic approaches
Int J Dev Neurosci. 2017; 57: 46-55. IF: 2.046
4. **FRENCH JA, KOEPP M, NAEGELIN Y, VIGEVANO F, AUVIN S, RHO JM, ROSENBERG E, DEVINSKY O, OLOFSSON PS, DICHTER MA**
Clinical studies and anti-inflammatory mechanisms of treatments
Epilepsia 2017; 58 (Suppl. 3):69-82. IF: 5.295
5. **DECARD BF, NAGY S, GARCIA M, FUHR P**
An unusual case of bilateral peroneal palsies due to fabellae
Neurology 2017; 88(9): 918. IF: 8.320
6. **DERFUSS T, KAPPOS L**
PML risk and natalizumab: the elephant in the room
Lancet Neurol. 2017; 16(11):864-865. IF: 26.284
7. **DOBSON R, KUHLE J, MIDDELDORP J, GIOVANNONI G** on behalf of the International CIS Study Investigators
Epstein-Barr negative multiple sclerosis: a true phenomenon?
Neurol Neuroimmunol Neuroinflamm. 2017; 4(2): e318. IF: -
8. **ENGELBORGH S, NIEMANTSVERDIET E, STRUYFS H, BLENNOW K, BROUNS R, COMABELLA M, DUJMOVIC I, VAN DER FLIER W, FRÖLICH L, GALIMBERTI D, GNANAPAVAN S, HEMMER B, HOFF E, HORT J, IACOBAEUS E, INGELSSON M, JAN DE JONG F, JONSSON M, KHALIL M, KUHLE J, LLEÓ A, DE MENDONÇA A, MOLINUEVO JL, NAGELS G, PAQUET C, PARNETTI L, ROKS G, ROSA-NETO P, SCHELTENS P, SKÅRSGÅRD C, STOMRUD E, TUMANI H, VISSER PJ, WALLIN A, WINBLAD B, ZETTERBERG H, DUIS F, TEUNISSEN CE**
Consensus guidelines for lumbar puncture in patients with neurological diseases
Alzheimers Dement (Amst) 2017; 18(8):111-126. IF: 9.478
9. **ENGELTER ST, TRAENKA C, LYRER P**
Dissection of cervical and cerebral arteries
Curr Neurol Neurosci Rep. 2017; 17:59. IF: 3.345
10. **ENGELTER ST, TRAENKA C, LYRER PA**
Stroke Caused by Cervical Artery Dissection
Bookchapter, In: Seung-Hoon Lee (Ed.): Stroke Revisited: Diagnosis and Treatment of Ischemic Stroke. Springer Science+Business Media Singapore; 2017: 189-198
11. **HARDMEIER M, LEOCANI L, FUHR P**
A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS
Multiple Scler. 2017; 23: 1309-1319. IF: 4.840
12. **HAUSER SL, BELACHEW S, KAPPOS L**
Ocrelizumab in primary progressive and relapsing Multiple Sclerosis
N Engl J Med 2017; 376(17): 1694. IF: 72.406
13. **HERT L, PETERS N**
Kleine Blutungen mit großer Bedeutung?
Ärztliche Praxis Neurologie Psychiatrie. 2017;1:20-23. IF: -
14. **HORVATH A, PEZOLD S, WEIGEL M, PARMAR K, CATTIN P**
High order slice interpolation for medical images
In: Tsiftaris S., Gooya A., Frangi A., Prince J. (Eds.) Simulation and Synthesis in Medical Imaging. SASHIMI 2017. Lecture Notes in Computer Science, Vol. 10557. Springer, Cham. IF: -
15. **KAPPOS L**
Comment on Retraction: Sato et al.: Risedronate therapy for prevention of hip fracture after stroke in elderly women: Reply from the authors
Neurology 2017; 88(2):221. IF: 8.320
16. **LASCANO AM, LALIVE PH, HARDMEIER M, FUHR P, SEECK M**
Clinical evoked potentials in neurology: a review of techniques and indications
Journal of Neurology, Neurosurgery & Psychiatry 2017; 88: 688-696. IF:7.349

17. **PAPADOPOULOU A, DERFUSS T, SPRENGER T**
Daclizumab for the treatment of multiple sclerosis
Neurodegener Dis Manag. 2017; 7(5):279-297. IF: -
18. **PETERS N**
Blutdrucktherapie beim akuten Schlaganfall
Leading Opinions – Innere Medizin 2017; 5:44-46. IF: -
19. RITZ M-F, **PETERS N, LYRER P**
Hereditary versus sporadic cerebral small vessel diseases: what makes the differences?
Journal of Cerebral Blood Flow and Metabolism, 2017, 37:1(S1). IF: 5.081
20. **RÜEGG S, IRAN SR**
The trouble with plasma cells. Getting to the root cause. Editorial.
Neurology 2017; 88: 340-341. IF: 8.320
21. **RÜEGG S**
Nicht-convulsiver Status epilepticus des Erwachsenen: Typen, Pathophysiologie, Epidemiologie, Ursachen und Diagnose
Akt Neurol 2017; 44:09. IF: 0.320
22. **RÜEGG S**
Nonconvulsive status epilepticus in adults: Types, pathophysiology, epidemiology, etiology, and diagnosis
Neurol Int Open 2017; 1: E189-E203. IF: -
23. **RÜEGG S**
Zukünftige Antiepileptika
Epileptologie 2017; 34: 87-99. IF: -
24. **SCHLEMM S, NOLTE CH, ENGELTER ST, ENDRES M, EBINGER M**
Cervical artery dissection after sports – An analytical evaluation of 190 published cases
European Stroke Journal 2017; 2(4): 335-345. IF: -
25. **SCOLDING NJ, PASQUINI M, REINGOLD SC, COHEN JA; International Conference on Cell-Based Therapies for Multiple Sclerosis (including DERFUSS T)**
Cell-based therapeutic strategies for multiple sclerosis
Brain 2017; 140(11):2776-2796 IF: 10.292
26. **VEZZANI A, RÜEGG S**
Introduction to the 2nd Meeting on Immunity and Inflammation in Epilepsy (IIE2016)
Epilepsia 2017; 58(Suppl 3): S7-S10. IF: 5.295
27. **WENDEBOURG MJ, HEESEN C, FINLAYSON M, MEYER B, POETTGEN J, KOEPKE S**
Patient education for people with multiple sclerosis-associated fatigue: A systematic review
PLoS One 2017;12(3):e0173025. IF: 2.806
28. **ZIEMSEN T, ROTHENBACHER D, KUHLE J, BERGER T**
Real-world evidence: Benefits and limitations in multiple sclerosis research
Nervenarzt 2017; 88(10):1153-1158. IF: 0.872